Earlier this week, Amazon Web Services (AWS) announced a partnership with Memorial Sloan Kettering Cancer Center (MSK) aimed at combating the projected increase of annual cancer deaths, which is expected to reach 15 million by 2040. The collaboration leverages artificial intelligence, high-performance computing, and cloud technology to enhance cancer research and personalized treatment development. By utilizing deidentified genomic, imaging, and clinical data, the project seeks to create a comprehensive longitudinal data resource for cancer research and improve validation processes.
Dr. Anaeze Offodile II, MSK’s Chief Strategy Officer, emphasized the shared commitment to accelerate innovations in cancer care through this partnership. AWS’s platforms, including Bedrock and SageMaker, will facilitate managing data quality and enhancing analytical capabilities, allowing for in-depth tracking of patient cancer progression and clinical responses.
Additionally, the partnership will bolster MSK’s Innovation Hub, which focuses on developing digital solutions for oncology challenges and supporting technology pilots through dedicated funding and AWS expertise. This collaboration also extends to AI-driven drug discovery efforts targeting high-unmet need cancers and orphan diseases.
The combined strengths of MSK’s extensive cancer research and AWS’s technological capabilities position this partnership as a significant step towards improving patient care and outcomes in the cancer treatment landscape.